Bantwal Baliga, MD
Endocrinology, Diabetes & Metabolism · Opelika, ALNPI 1992847669
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $352,842 of the $482,685 with a category attached, or 73.1%. 60 manufacturers reported payments, led by Lilly USA, LLC at 26.7% of the total. Among endocrinology, diabetes & metabolism clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,912 payments — averaging $252.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$129K
- Novo Nordisk$120K
- Abbott$77K
- Boehringer Ingelheim$42K
- AstraZeneca$37K
- Amarin Pharma, Inc.$30K
- plus $47K from 54 others
What the payments were for
- Consulting fees$24,5255%
- Speaking & faculty fees$352,84273%
- Travel & lodging$62,30013%
- Food & beverage$42,7079%
- Education$2520%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$78,403
- ZEPBOUND$75,498
- FREESTYLE LIBRE 3$65,313
- RYBELSUS$63,978
- Ozempic$34,863
- FARXIGA$34,797
- Vascepa$29,608
- Tresiba$13,592
- iLet Bionic Pancreas$5,507
- Eversense$5,154
- BIGFOOT UNITY DIABETES MANAGEMENT SYSTEM$4,982
- STEGLATRO$4,742
- EVERSENSE E3 SENSOR KIT - RETAIL$2,700
- FreeStyle Libre Pro$2,300
- FreeStyle Libre$1,853
- UNITY DIABETES MANAGEMENT SYSTEM$1,603
- t-slim insulin pump$1,600
- GVOKE HYPOPEN$1,540
- ZEGALOGUE$1,200
- iLet Insulin Infusion Kit Inset$787
How this compares
$482,685 in reported general payments places this provider in the 95th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 21 | $942,759 |
| OzempicSemaglutide | 545 | $636,722 |
| CrysvitaBurosumab-Twza | 24 | $288,454 |
| MounjaroTirzepatide | 224 | $282,886 |
| JardianceEmpagliflozin | 260 | $239,916 |
| FarxigaDapagliflozin Propanediol | 166 | $164,385 |
| TrulicityDulaglutide | 74 | $92,298 |
| V-Go 30Sub-Q Insulin Device, 30 Unit | 111 | $75,103 |
| Tresiba Flextouch U-100Insulin Degludec | 118 | $71,213 |
| KerendiaFinerenone | 80 | $68,156 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 100 | $66,743 |
| AfrezzaInsulin Regular, Human | 43 | $58,710 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $56,398 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 34 | $49,093 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 55 | $38,487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $479 | $942,75921 claims |
| Novo NordiskOzempic, Novolog, Rybelsus, Fiasp | $119,652 | $727,196702 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro | $128,973 | $414,557499 claims |
| Kyowa Kirin, Inc.Crysvita | $367 | $288,45424 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $42,023 | $247,176272 claims |
| AstraZenecaFarxiga | $36,963 | $164,385166 claims |
| BayerKerendia | $2,020 | $68,15680 claims |
| Mannkind CorporationAfrezza | $1,147 | $58,71043 claims |
| PfizerGenotropin | $34 | $32,58016 claims |
| AmgenProlia | $882 | $20,56912 claims |
| MerckJanuvia | $5,220 | $19,78726 claims |
| AbbVieSynthroid | $154 | $6,79174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Opelika
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
- David BellIrondale$112K
- Bethany JacksonFlorence$90K
- Dwain WoodeHuntsville$78K
- Fernando BrilBirmingham$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.